Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers at Scripps Research Institute have successfully synthesized a highly complex, plant-derived compound called ingenol, which has long been of interest for its potential in treating various cancers. The efficient chemical synthesis will enable scientists to investigate the therapeutic properties of ingenol derivatives and pote...
Researchers identified Skp2 inhibitor that blocks malignancy-promoting effects, shrinks tumors in preclinical studies. The compound suppresses prostate cancer stem cells, which play a role in cancer initiation and progression.
Researchers discovered a novel protein called ceramide-1 phosphate transport protein (CPTP), which regulates biologically active lipids and plays a role in cell signaling. The study sheds light on the cellular mechanisms contributing to diseases like cancer, asthma, and thrombosis.
Rapamycin treatment improved memory, reduced thyroid follicle size, and decreased cancer rates in older mice. However, its effects were age-independent, with similar benefits seen in young mice, suggesting a potential use for relieving some age-related conditions.
Scientists at Cancer Research UK have discovered a new molecule that prevents cancer cells from responding to low oxygen levels, targeting the master switch HIF-1. The researchers developed this approach using synthetic biology and testing over 3.2 million potential compounds.
Researchers discovered a function of PTEN that helps explain why certain therapies fail in many cancer patients. The finding increases understanding of molecular mechanisms and provides clues for individualizing therapy for patients with PTEN-deficient tumors.
A team led by Fred Hutchinson Cancer Research Center scientists is developing precision therapies that selectively kill cancer cells while sparing normal tissue. Using high-throughput screening, they aim to identify new genes to target that may be highly specific to each patient's tumor.
Researchers developed new compounds that mimic catestatin, a naturally used blood pressure regulator. The findings suggest these compounds could be used to control hypertension and potentially lead to new treatments for the disease.
Malpractice claims in primary care mainly stem from missed diagnoses of cancer, heart attack, and meningitis, with a substantial proportion of deaths attributed to these errors. Drug errors also account for a significant share of claims, although rates vary across countries.
Researchers at UCSF have discovered a way to indirectly target myc-driven tumors using an experimental drug that targets the mTOR protein. Clinical trials for this new treatment approach may soon be available for patients with myc-driven cancers.
Researchers have developed a promising new cancer treatment, PAC-1, which targets a cellular enzyme to spur cancer cells to self-destruct. The compound has shown safe and anti-cancer effects in cell culture, mouse models, and pet dogs with spontaneously occurring cancers.
Scientists at Nanyang Technological University (NTU) have developed a new technique called Cellular Thermal Shift Assay (CETSA) that can accurately determine if a drug has reached its target protein in the human body. This breakthrough method will help reduce the costly and time-consuming trial-and-error process of drug development.
Researchers have discovered novel compounds that fine-tune the activity of cells' protein-disposing machinery, which can help target solid tumors. These 'allosteric regulators' show promise as anti-cancer therapies without inducing drug resistance.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have identified specific types of intestinal bacteria that contribute to the development of lymphoma. These bacteria can be targeted with antibiotics to reduce cancer risk, while promoting protective bacteria through probiotics may also be effective.
Researchers generated a comprehensive list of cancer-specific genetic variations and made them available to the public. The extensive data set has the potential to dramatically enhance understanding of relationships between specific cancer-related genetic variations and drug response.
Recent studies have found chemotherapy-associated adverse neurological effects, including vascular complications and neuropathic pains. Chemotherapy triggers changes in ion channels on dorsal root ganglia, resulting in secondary changes that affect neurogenesis and plasticity.
Researchers have gained groundbreaking knowledge about proteases, enzymes that play a role in cancer cell development. The study reveals that proteases can bind to each other instead of just cleaving, which may lead to the development of new anticancer drugs.
Researchers at Sanford-Burnham Medical Research Institute have developed nanoparticles that can deliver small interfering RNA molecules to specific cells, effectively silencing malfunctioning genes. The approach points toward new ways to treat diseases such as cancer and heart disease by using RNA interference.
Researchers have discovered genetic processes that cause specific types of bowel cancer and identified effective drugs targeting these genes. The findings offer the opportunity to develop personalized treatment based on a person's genetic profile, with promising results for alternative second- or third-line treatments.
A team of scientists at Cold Spring Harbor Laboratory has discovered a way to prevent pancreatic tumor cells from responding to chemotherapy. The antibody FG-3019 targets survival cues inside the tumor mass, increasing the effectiveness of treatment and reducing drug resistance.
Scientists have developed a roadmap for ATP-binding cassette (ABC) transporter proteins, crucial components of every cell that are involved in tumor resistance and disease. Understanding how these proteins interact with other vital components can help develop targeted drugs to treat diseases such as cystic fibrosis, cancer, and others.
A new study has revealed that the COX-2 enzyme is largely absent from major blood vessels, instead found in brain, kidney, thymus, and gut. This knowledge paves the way for the development of safer, more targeted drugs for arthritis patients with fewer side effects.
Researchers at ETH Zurich developed a new PET tracer that targets the folic acid receptor on cancer cells, enabling precise diagnosis and predicting patient response to therapy. The tracer also has potential for displaying inflammatory diseases and medication development.
A new treatment approach using MGN1703, a small DNA molecule that stimulates the immune system, has shown promise in prolonging progression-free survival in patients with metastatic colorectal cancer. The drug is designed to broadly activate all components of the innate immune system to destroy cancer cells.
A phase III trial found that adding chemotherapy to surgery after curative D2 gastrectomy improved 5-year survival by 34% compared to surgery alone. The study, CLASSIC, added combination chemotherapy (XELOX) to standard treatment, showing a significant reduction in cancer-related death.
A new study by RI-MUHC researchers identifies a previously unknown mode of cancer progression, where infection-fighting white blood cells activate cancer cells and facilitate their spread to secondary tumours. Medications already used for other non-cancer diseases may prevent this mechanism of cancer spread or metastasis.
The foundation awarded six new Clinical Investigators, including Omar Abdel-Wahab and Himisha Beltran, for their cancer research programs. The recipients will receive $450,000 each, while three others received Continuation Grants worth $300,000 to support ongoing research.
Researchers at USC Norris Comprehensive Cancer Center have discovered a promising new way to treat primary effusion lymphoma (PEL), a rare and aggressive blood cancer often found in people with HIV. BRD4 inhibitors show effectiveness against PEL, which has a poor prognosis, offering hope for new therapies.
The USPSTF recommends screening for hepatitis C virus (HCV) infection in persons at high risk for infection. One-time screening for all adults born between 1945 and 1965 may identify infected patients at an earlier, more treatable stage of disease.
A Stanford-led study found that men diagnosed with azoospermia have a significantly higher risk of developing cancer than the general population. The study, which analyzed data from over 2,200 infertile men, found that azoospermic men were nearly three times more likely to receive a cancer diagnosis than non-azoospermic men.
Researchers at Scripps Research Institute receive $1.4 million from the National Cancer Institute to create a potential new drug targeting malignant cells in CLL, while sparing normal tissues. The study aims to deliver cytotoxic drugs with specific targeting using cell surface receptor TOSO and receptor tyrosine kinase ROR1.
Harvard researchers have identified the SALL4 gene as a key player in tumor formation, and have demonstrated that blocking its activity can halt cancer growth. The study provides new hope for treating aggressive forms of leukemia and other cancers.
A new drug called pyrvinium pamoate inhibits aggressive prostate cancer resistant to standard drugs by binding to a different site on the AR and inhibiting its activity without preventing androgen binding. This unique mechanism of action has the potential to treat cancers resistant to currently approved therapies.
Researchers at Northwestern University have found a molecular pathway that prevents the death of immature ovarian eggs due to chemotherapy, potentially preserving fertility and endocrine function. Adding a specific chemotherapy drug combination may protect young women's reproductive health during cancer treatment.
A study shows that bazedoxifene, an approved osteoporosis drug, inhibits estrogen-induced gene expression and cell proliferation in breast cancer cells. The medication also reduced estrogen activity and estrogen receptor levels in cultured human breast cancer cells.
Researchers have found that bazedoxifene can stop the growth of breast cancer cells, including those with resistance to current targeted therapies. The study suggests that bazedoxifene's unique mechanism of action may make it a viable treatment option for patients with advanced breast cancer.
Researchers found that a developmental protein called ROR1 promotes cancer metastasis by regulating epithelial-mesenchymal transition. Silencing ROR1 reverses this process and inhibits tumor growth in animal models.
The Society of Interventional Radiology has selected 18 new Fellows who have demonstrated excellence in research and publishing or teaching and leadership within the field. These individuals will play key roles in advancing the science and technology of interventional radiology.
Researchers identified two gene variants that can predict which women are most likely to benefit from breast cancer prevention treatment and which should avoid it. The study found that women with the beneficial version of the two SNPs were 5.71 times less likely to develop breast cancer while taking preventive drugs.
Researchers used nanosensors and advanced imaging techniques to track the spread of pancreatic tumors and monitor the effectiveness of drugs. The study reveals promising results for combination therapies that can enhance drug delivery and improve clinical outcomes.
Researchers found that none of the 169 cancer clinical practice guidelines met all eight criteria set by the Institute of Medicine. However, some guidelines were rated as 'good,' highlighting the need for a balance between ideal standards and practical implementation.
A study found that rod-shaped nanoparticles adhere effectively to endothelial cells, enhancing drug delivery. Researchers believe this technology holds promise for novel targeted therapies with fewer side effects.
ACS honors Stephen J. Lippard, Ph.D. for his groundbreaking work in inorganic chemistry, paving the way for improvements in human health and cancer treatment.
Researchers developed a new treatment combining chemotherapy and radioimmunotherapy, which showed significant improvement in survival rates without recurrence. Patients who received this treatment had a 64% chance of survival and a 100% chance of survival at two-year follow-up.
A joint investigation by BMJ and Channel 4 Dispatches found that evidence of potential harm from new diabetes drugs has not been fully published. This has led to millions of patients worldwide being under-informed about possible risks. Regulators in Europe and the US have faced criticism for their slow response to emerging concerns.
Researchers identified novel FGFR gene fusions across various cancer types, suggesting potential therapeutic targets for patients. The study's findings have the potential to identify actionable mutations that can be treated with precision therapies.
Recent data suggest that aspirin reduces heart attacks, but also increases risk of gastrointestinal bleeding and stroke. The study found that including a cancer mortality benefit influences aspirin prescribing thresholds, making middle-aged men eligible for prevention.
Researchers Brian Druker and Charles Sawyers developed imatinib, a widely used drug targeting cancer cells, transforming chronic myeloid leukemia from fatal to manageable. Their work inspired the pharmaceutical industry and future physician-scientists.
A new study released by George Mason University researchers has shown success in pinpointing individualized treatment for women with metastatic breast cancer. The pilot study combined proteomic and genomic research, achieving a 30% increase in progression-free survival for nearly half of the patients.
Scientists developed a potential new drug that destroys cancer cells while preventing their spread to other sites in the body. The compound was tested in laboratory mice and showed promising results.
Frailty affects 5-10% of people over 70, leading to increased death rates, poor function, and hospitalizations. Screening with the FRAIL questionnaire can identify frail individuals and guide treatment with exercise, nutrition supplements, vitamin D, and reduced medications.
A Singapore research team has identified a protein enzyme, MNK kinase, as a key player in the progression of chronic myeloid leukemia (CML) to its deadly terminal stage. The researchers found that targeting this enzyme could help prevent cancer stem cells from developing drug resistance and improve patient survival.
A recent study by researchers at the University of Pennsylvania found that cancer drug shortages have left physicians unable to prescribe standard chemotherapies for a range of cancers. As a result, many doctors are forced to delay or substitute treatment, leading to increased costs and potential harm to patients.
Researchers have discovered a new oncogene, NTRK1, that drives a subset of lung cancers. A novel targeted treatment approach has been proposed, with preclinical studies showing effective silencing of mutated NTRK1 genes using specific compounds.
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are testing the safety of Nivolumab, a PD-1 receptor blocking antibody, in combination with other drugs in patients with metastatic renal cell carcinoma. The study aims to assess safety and tolerability, as well as preliminary antitumor activity.
A randomized phase III trial found sorafenib stops tumor growth and provides effective treatment for thyroid cancer patients who progress following standard therapies. The therapy also thwarts disease progression even among those whose tumors do not regress, with median progression-free survival of 10.8 months.
Researchers have discovered a new oncogene, RET rearrangement, which is present in 15.7% of lung adenocarcinoma patients and may be targeted with existing tyrosine-kinase inhibitors. This finding presents a promising treatment option for patients with this specific mutation.
Researchers found that combining ipilimumab and nivolumab led to long-lasting tumor shrinkage in over half of patients with metastatic melanoma. The combination resulted in a 50% tumor size reduction in 40% of patients, with some experiencing shrinkages of over 80% within 12 weeks.
A new drug called lambrolizumab has shown promising results in treating patients with advanced melanoma, with 77% of patients experiencing tumor response and minimal serious side effects. The treatment works by blocking a protein that allows cancer cells to hide from the immune system, reactivating an immune response to attack the cancer.
Doctors at WashU Medicine have shown that testing cervical tumors before treatment can predict whether patients will do well with standard chemotherapy. The study supports personalized medicine for cervical cancer, a tumor normally treated with a one-size-fits-all approach.